A detailed history of Janus Henderson Group PLC transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 598,122 shares of RYTM stock, worth $35.6 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
598,122
Previous 593,642 0.75%
Holding current value
$35.6 Million
Previous $24.4 Million 28.56%
% of portfolio
0.02%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$40.81 - $55.0 $182,828 - $246,400
4,480 Added 0.75%
598,122 $31.3 Million
Q2 2024

Aug 14, 2024

SELL
$35.41 - $44.37 $983,866 - $1.23 Million
-27,785 Reduced 4.47%
593,642 $24.4 Million
Q1 2024

May 15, 2024

SELL
$39.12 - $52.44 $18,190 - $24,384
-465 Reduced 0.07%
621,427 $26.9 Million
Q4 2023

Feb 14, 2024

SELL
$21.39 - $49.64 $9.49 Million - $22 Million
-443,853 Reduced 41.65%
621,892 $28.6 Million
Q3 2023

Nov 14, 2023

SELL
$15.81 - $27.8 $197,024 - $346,443
-12,462 Reduced 1.16%
1,065,745 $24.4 Million
Q2 2023

Aug 14, 2023

SELL
$16.32 - $21.15 $316,053 - $409,590
-19,366 Reduced 1.76%
1,078,207 $17.8 Million
Q1 2023

May 15, 2023

SELL
$16.88 - $34.24 $2.41 Million - $4.88 Million
-142,580 Reduced 11.5%
1,097,573 $19.6 Million
Q4 2022

Feb 14, 2023

SELL
$22.21 - $30.25 $7.13 Million - $9.71 Million
-320,930 Reduced 20.56%
1,240,153 $36.1 Million
Q3 2022

Nov 14, 2022

SELL
$4.3 - $30.85 $2.23 Million - $16 Million
-518,994 Reduced 24.95%
1,561,083 $38.2 Million
Q2 2022

Aug 15, 2022

SELL
$3.12 - $12.25 $2.72 Million - $10.7 Million
-870,925 Reduced 29.51%
2,080,077 $8.63 Million
Q1 2022

May 16, 2022

SELL
$6.13 - $12.24 $1.12 Million - $2.24 Million
-182,933 Reduced 5.84%
2,951,002 $34 Million
Q4 2021

Feb 14, 2022

SELL
$8.62 - $13.9 $417,613 - $673,413
-48,447 Reduced 1.52%
3,133,935 $31.3 Million
Q3 2021

Nov 16, 2021

SELL
$11.68 - $20.72 $8.69 Million - $15.4 Million
-743,668 Reduced 18.94%
3,182,382 $41.6 Million
Q2 2021

Aug 16, 2021

SELL
$18.52 - $22.55 $3 Million - $3.65 Million
-161,973 Reduced 3.96%
3,926,050 $76.9 Million
Q1 2021

May 17, 2021

SELL
$20.25 - $39.49 $8.18 Million - $15.9 Million
-403,742 Reduced 8.99%
4,088,023 $87 Million
Q4 2020

Feb 16, 2021

BUY
$21.17 - $32.61 $2.23 Million - $3.44 Million
105,395 Added 2.4%
4,491,765 $134 Million
Q3 2020

Nov 16, 2020

SELL
$18.13 - $30.61 $437,259 - $738,251
-24,118 Reduced 0.55%
4,386,370 $95.1 Million
Q2 2020

Aug 14, 2020

BUY
$14.41 - $25.35 $1.32 Million - $2.32 Million
91,455 Added 2.12%
4,410,488 $98.4 Million
Q1 2020

May 14, 2020

BUY
$13.16 - $22.9 $181,410 - $315,676
13,785 Added 0.32%
4,319,033 $65.7 Million
Q4 2019

Feb 18, 2020

BUY
$19.53 - $25.5 $17.5 Million - $22.9 Million
898,500 Added 26.37%
4,305,248 $98.8 Million
Q3 2019

Nov 14, 2019

BUY
$18.62 - $24.51 $2.13 Million - $2.8 Million
114,423 Added 3.48%
3,406,748 $73.6 Million
Q2 2019

Jul 31, 2019

BUY
$21.11 - $28.48 $222,837 - $300,634
10,556 Added 0.32%
3,292,325 $72.4 Million
Q1 2019

Apr 30, 2019

BUY
$24.76 - $31.66 $460,387 - $588,686
18,594 Added 0.57%
3,281,769 $90 Million
Q4 2018

Feb 06, 2019

BUY
$24.11 - $31.34 $5.12 Million - $6.65 Million
212,337 Added 6.96%
3,263,175 $87.7 Million
Q3 2018

Nov 09, 2018

BUY
$26.99 - $35.85 $20.5 Million - $27.2 Million
759,053 Added 33.12%
3,050,838 $89 Million
Q2 2018

Aug 10, 2018

BUY
$17.02 - $35.2 $20.4 Million - $42.1 Million
1,197,165 Added 109.37%
2,291,785 $71.6 Million
Q1 2018

May 14, 2018

BUY
$19.9 - $32.25 $6.76 Million - $10.9 Million
339,460 Added 44.95%
1,094,620 $21.8 Million
Q4 2017

Feb 09, 2018

BUY
$22.0 - $30.51 $16.6 Million - $23 Million
755,160
755,160 $21.9 Million

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $3.31B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.